600812.SH
华北制药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 4.61
−6.11%Aug 27, 2026, 08:42 UTC
North China Pharmaceutical's subsidiary Shenzhen Huayao South Pharmaceutical received approval from China's National Medical Products Administration on August 24, 2026, to add a 1.8g specification of lysine acetylsalicylate for injection, with both 0.9g and 1.8g specifications passing generic drug consistency evaluation.
Source:Aug 21, 2026, 11:36 UTC
North China Pharmaceutical announced its first-half 2026 results: revenue of 4.220 billion yuan, down 20.01% year-on-year; net profit attributable to shareholders of 63.8459 million yuan, down 48.30% year-on-year.
Source:Aug 21, 2026, 11:36 UTC
North China Pharmaceutical's subsidiary Jintan received approval from China's National Medical Products Administration to conduct clinical trials for a hexavalent recombinant norovirus vaccine.
Source:Aug 3, 2026, 08:25 UTC
North China Pharmaceutical and its subsidiaries Huamin Company and Nanfang Company had 8 drugs preliminarily selected in the 12th national centralized drug procurement, with the publicity period from July 31 to August 5, 2026, and the procurement cycle ending December 31, 2029.
Source: